Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1994 Apr;144(4):735–746.

Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer.

J A Ruizeveld de Winter 1, P J Janssen 1, H M Sleddens 1, M C Verleun-Mooijman 1, J Trapman 1, A O Brinkmann 1, A B Santerse 1, F H Schröder 1, T H van der Kwast 1
PMCID: PMC1887232  PMID: 7512791

Abstract

Heterogeneity in human androgen receptor (hAR) expression in prostate cancer is considered to be implicated in tumor progression. hAR expression was therefore studied immunohistochemically in localized and locally progressive, hormone refractory (HR) prostate cancer. Because altered functional activity of the hAR may be due to changes in the structural integrity of the hAR gene, exons 2 to 8 of the hAR gene were assessed for mutations by single-strand conformation polymorphism (SSCP) analysis and exon 1 was analyzed for the size of the CAG repeat. The hormone binding capacity, a prerequisite for ligand-regulated receptor function, was determined by a ligand binding assay. Coexpression of the hAR and prostate-specific antigen (PSA) was studied by a sequential double immunoenzymatic staining to verify whether PSA expression is a parameter of hAR function. Almost all human prostatic carcinomas revealed heterogeneous hAR expression, regardless of tumor differentiation and progression. Putative predominance of hAR-negative tumor areas in HR prostate cancer was not observed. No hAR gene mutations or major changes in the CAG repeat were found in the 18 HR carcinomas or in the 9 control samples. Moreover, all selected hAR-expressing cancers were able to bind the synthetic androgen methyltrienolone (R1881). Immunoenzymatic double staining revealed even PSA expression in hAR-negative tumor areas. PSA immunohistochemistry in human prostatic carcinomas therefore is of no use in determining hAR functional activity. Thus, most prostatic carcinomas, even when progressed to a state of hormone insensitivity, contain a structurally intact hAR gene, heterogeneously expressed with retained androgen binding capacity.

Full text

PDF
735

Images in this article

739Figure 1
on p.739
742Figure 3
on p.742
742Figure 4
on p.742
743Figure 5
on p.743

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsson P. A., Lilja H., Falkmer S., Wadström L. B. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate. 1988;12(1):39–46. doi: 10.1002/pros.2990120106. [DOI] [PubMed] [Google Scholar]
  2. Barrack E. R., Tindall D. J. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer. Prog Clin Biol Res. 1987;239:155–187. [PubMed] [Google Scholar]
  3. Bennett B. D. Histochemistry and quantitative microscopy of prostate cancer. Prog Clin Biol Res. 1987;239:711–758. [PubMed] [Google Scholar]
  4. Benson R. C., Jr, Gorman P. A., O'Brien P. C., Holicky E. L., Veneziale C. M. Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer. 1987 May 1;59(9):1599–1606. doi: 10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  5. Bruchovsky N., Brown E. M., Coppin C. M., Goldenberg S. L., Le Riche J. C., Murray N. C., Rennie P. S. The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res. 1987;239:347–387. [PubMed] [Google Scholar]
  6. Chodak G. W., Kranc D. M., Puy L. A., Takeda H., Johnson K., Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol. 1992 Mar;147(3 Pt 2):798–803. doi: 10.1016/s0022-5347(17)37389-5. [DOI] [PubMed] [Google Scholar]
  7. Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cronauer M. V., Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate. 1993;22(1):11–22. doi: 10.1002/pros.2990220103. [DOI] [PubMed] [Google Scholar]
  8. Edwards A., Hammond H. A., Jin L., Caskey C. T., Chakraborty R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992 Feb;12(2):241–253. doi: 10.1016/0888-7543(92)90371-x. [DOI] [PubMed] [Google Scholar]
  9. Gallee M. P., Visser-de Jong E., van der Korput J. A., van der Kwast T. H., ten Kate F. J., Schroeder F. H., Trapman J. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res. 1990;18(3):181–187. doi: 10.1007/BF00295844. [DOI] [PubMed] [Google Scholar]
  10. Gallee M. P., van Steenbrugge G. J., ten Kate F. J., Schroeder F. H., van der Kwast T. H. Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: potential application for hormone therapy monitoring. J Natl Cancer Inst. 1987 Dec;79(6):1333–1340. [PubMed] [Google Scholar]
  11. Gallee M. P., van Vroonhoven C. C., van der Korput H. A., van der Kwast T. H., ten Kate F. J., Romijn J. C., Trapman J. Characterization of monoclonal antibodies raised against the prostatic cancer cell line PC-82. Prostate. 1986;9(1):33–45. doi: 10.1002/pros.2990090107. [DOI] [PubMed] [Google Scholar]
  12. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  13. Gittes R. F. Carcinoma of the prostate. N Engl J Med. 1991 Jan 24;324(4):236–245. doi: 10.1056/NEJM199101243240406. [DOI] [PubMed] [Google Scholar]
  14. Gleason D. F. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966 Mar;50(3):125–128. [PubMed] [Google Scholar]
  15. Gorelic L. S., Lamm D. L., Ramzy I., Radwin H. M., Shain S. A. Androgen receptors in biopsy specimens of prostate adenocarcinoma. Heterogeneity of distribution and relation to prognostic significance of receptor measurements for survival of advanced cancer patients. Cancer. 1987 Jul 15;60(2):211–219. doi: 10.1002/1097-0142(19870715)60:2<211::aid-cncr2820600216>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  16. Hsieh J. T., Wu H. C., Gleave M. E., von Eschenbach A. C., Chung L. W. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res. 1993 Jun 15;53(12):2852–2857. [PubMed] [Google Scholar]
  17. Hulka B. S., Beckman W. C., Jr, Checkoway H., DiFerdinando G., Hammond J. E., Fried F. A., Mickey D. D., Stumpf W. E., Clark T. D. Androgen receptors detected by autoradiography in prostatic carcinoma and benign prostatic hyperplastic tissue. Prostate. 1987;10(3):223–233. doi: 10.1002/pros.2990100305. [DOI] [PubMed] [Google Scholar]
  18. Isaacs J. T. New principles in the management of metastatic prostatic cancer. Prog Clin Biol Res. 1985;185A:383–405. [PubMed] [Google Scholar]
  19. La Spada A. R., Wilson E. M., Lubahn D. B., Harding A. E., Fischbeck K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991 Jul 4;352(6330):77–79. doi: 10.1038/352077a0. [DOI] [PubMed] [Google Scholar]
  20. Labrie F. Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am. 1991 Dec;20(4):845–872. [PubMed] [Google Scholar]
  21. Labrie F., Luthy I., Veilleux R., Simard J., Bélanger A., Dupont A. New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res. 1987;243A:145–172. [PubMed] [Google Scholar]
  22. Masai M., Sumiya H., Akimoto S., Yatani R., Chang C. S., Liao S. S., Shimazaki J. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate. 1990;17(4):293–300. doi: 10.1002/pros.2990170405. [DOI] [PubMed] [Google Scholar]
  23. McPhaul M. J., Marcelli M., Tilley W. D., Griffin J. E., Wilson J. D. Androgen resistance caused by mutations in the androgen receptor gene. FASEB J. 1991 Nov;5(14):2910–2915. doi: 10.1096/fasebj.5.14.1752359. [DOI] [PubMed] [Google Scholar]
  24. Mullink H., Henzen-Logmans S. C., Alons-van Kordelaar J. J., Tadema T. M., Meijer C. J. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1986;52(1):55–65. doi: 10.1007/BF02889950. [DOI] [PubMed] [Google Scholar]
  25. Newmark J. R., Hardy D. O., Tonb D. C., Carter B. S., Epstein J. I., Isaacs W. B., Brown T. R., Barrack E. R. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6319–6323. doi: 10.1073/pnas.89.14.6319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  27. Power R. F., Mani S. K., Codina J., Conneely O. M., O'Malley B. W. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991 Dec 13;254(5038):1636–1639. doi: 10.1126/science.1749936. [DOI] [PubMed] [Google Scholar]
  28. Quarmby V. E., Beckman W. C., Jr, Cooke D. B., Lubahn D. B., Joseph D. R., Wilson E. M., French F. S. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res. 1990 Feb 1;50(3):735–739. [PubMed] [Google Scholar]
  29. Riegman P. H., Vlietstra R. J., van der Korput J. A., Brinkmann A. O., Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991 Dec;5(12):1921–1930. doi: 10.1210/mend-5-12-1921. [DOI] [PubMed] [Google Scholar]
  30. Ris-Stalpers C., Trifiro M. A., Kuiper G. G., Jenster G., Romalo G., Sai T., van Rooij H. C., Kaufman M., Rosenfield R. L., Liao S. Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics. Mol Endocrinol. 1991 Oct;5(10):1562–1569. doi: 10.1210/mend-5-10-1562. [DOI] [PubMed] [Google Scholar]
  31. Ruizeveld de Winter J. A., Trapman J., Vermey M., Mulder E., Zegers N. D., van der Kwast T. H. Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem. 1991 Jul;39(7):927–936. doi: 10.1177/39.7.1865110. [DOI] [PubMed] [Google Scholar]
  32. Rundlett S. E., Wu X. P., Miesfeld R. L. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol. 1990 May;4(5):708–714. doi: 10.1210/mend-4-5-708. [DOI] [PubMed] [Google Scholar]
  33. Sadi M. V., Barrack E. R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer. 1993 Apr 15;71(8):2574–2580. doi: 10.1002/1097-0142(19930415)71:8<2574::aid-cncr2820710823>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  34. Sadi M. V., Walsh P. C., Barrack E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991 Jun 15;67(12):3057–3064. doi: 10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  35. Sleddens H. F., Oostra B. A., Brinkmann A. O., Trapman J. Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res. 1992 Mar 25;20(6):1427–1427. doi: 10.1093/nar/20.6.1427-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stearns M. E., McGarvey T. Prostate cancer: therapeutic, diagnostic, and basic studies. Lab Invest. 1992 Nov;67(5):540–552. [PubMed] [Google Scholar]
  37. Trapman J., Ris-Stalpers C., van der Korput J. A., Kuiper G. G., Faber P. W., Romijn J. C., Mulder E., Brinkmann A. O. The androgen receptor: functional structure and expression in transplanted human prostate tumors and prostate tumor cell lines. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):837–842. doi: 10.1016/0960-0760(90)90429-o. [DOI] [PubMed] [Google Scholar]
  38. Têtu B., Srigley J. R., Boivin J. C., Dupont A., Monfette G., Pinault S., Labrie F. Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study. Am J Surg Pathol. 1991 Feb;15(2):111–120. doi: 10.1097/00000478-199102000-00002. [DOI] [PubMed] [Google Scholar]
  39. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  40. Veldscholte J., Voorhorst-Ogink M. M., Bolt-de Vries J., van Rooij H. C., Trapman J., Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta. 1990 Apr 9;1052(1):187–194. doi: 10.1016/0167-4889(90)90075-o. [DOI] [PubMed] [Google Scholar]
  41. Vernon S. E., Williams W. D. Pre-treatment and post-treatment evaluation of prostatic adenocarcinoma for prostatic specific acid phosphatase and prostatic specific antigen by immunohistochemistry. J Urol. 1983 Jul;130(1):95–98. doi: 10.1016/s0022-5347(17)50977-5. [DOI] [PubMed] [Google Scholar]
  42. Wolf D. A., Schulz P., Fittler F. Transcriptional regulation of prostate kallikrein-like genes by androgen. Mol Endocrinol. 1992 May;6(5):753–762. doi: 10.1210/mend.6.5.1376410. [DOI] [PubMed] [Google Scholar]
  43. Zegers N. D., Claassen E., Neelen C., Mulder E., van Laar J. H., Voorhorst M. M., Berrevoets C. A., Brinkmann A. O., van der Kwast T. H., Ruizeveld de Winter J. A. Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta. 1991 Jan 23;1073(1):23–32. doi: 10.1016/0304-4165(91)90178-j. [DOI] [PubMed] [Google Scholar]
  44. de Winter J. A., Trapman J., Brinkmann A. O., Boersma W. J., Mulder E., Schroeder F. H., Claassen E., van der Kwast T. H. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol. 1990 Apr;160(4):329–332. doi: 10.1002/path.1711600409. [DOI] [PubMed] [Google Scholar]
  45. van Aubel O., Bolt-de Vries J., Blankenstein M. A., Schröder F. H. Prediction of time to progression after orchiectomy by the nuclear androgen receptor content from multiple biopsy specimens in patients with advanced prostate cancer. Prostate. 1988;12(3):191–198. doi: 10.1002/pros.2990120302. [DOI] [PubMed] [Google Scholar]
  46. van der Kwast T. H., Schalken J., Ruizeveld de Winter J. A., van Vroonhoven C. C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 1991 May 10;48(2):189–193. doi: 10.1002/ijc.2910480206. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES